[HTML] springer.comFull View

[HTML][HTML] miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

S Caporali, A Amaro, L Levati, E Alvino… - Journal of Experimental …, 2019 - Springer
Background Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi)
remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma …
被引用次数：77 相关文章

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

S Caporali, A Amaro, L Levati, E Alvino… - … of Experimental & …, 2019 - go.gale.com
Background Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi)
remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma …

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.

S Caporali, A Amaro, L Levati, E Alvino… - … of Experimental & …, 2019 - search.ebscohost.com
Background: Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi)
remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma …

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.

S Caporali, A Amaro, L Levati, E Alvino… - … of Experimental & …, 2019 - europepmc.org
Background Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi)
remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma …

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

S Caporali, A Amaro, L Levati… - … of experimental & …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi)
remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma …
[HTML] biomedcentral.com

[HTML][HTML] miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

S Caporali, A Amaro, L Levati… - … of Experimental & …, 2019 - jeccr.biomedcentral.com
Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi) remains a great
challenge for targeted therapy in patients with BRAF-mutant melanoma. Here, we explored …
[PDF] archive.org

[PDF][PDF] miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

S Caporali, A Amaro, L Levati, E Alvino, PM Lacal… - 2019 - scholar.archive.org
Background: Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi)
remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma …

mir-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating adam9 and vegf-a

S Caporali, A Amaro, L Levati, E Alvino… - international journal of …, 2019 - scimatic.org
Background Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi)
remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma …
[HTML] nih.gov

[HTML][HTML] miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

S Caporali, A Amaro, L Levati, E Alvino… - … of Experimental & …, 2019 - ncbi.nlm.nih.gov
Background Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi)
remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma …
[PDF] academia.edu

[PDF][PDF] miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

S Caporali, A Amaro, L Levati, E Alvino, PM Lacal… - 2019 - academia.edu
Background: Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi)
remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma …